Physician profile
Meredith Baker
NPI 1346060936
$1,430.61
in general payments reported to CMS, 2019-2025
19 companies · $1,372 in 2025
The $1,372 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $58.61 · 2025: $1,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,430.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $257.41 | 2025 | |
| Pfizer INC. | $207.84 | 2025 | |
| Axsome Therapeutics, INC. | $178.82 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $149.00 | 2025 | |
| Lilly USA, LLC | $141.55 | 2025 | Zepbound, Mounjaro, Jardiance |
| Shield Therapeutics INC | $100.25 | 2024-2025 | |
| Novo Nordisk INC | $62.65 | 2025 | Wegovy |
| Glaxosmithkline, LLC. | $46.81 | 2025 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $39.83 | 2025 | The Cologuard Plus Collection Kit |
| Xeris Pharmaceuticals, INC. | $37.63 | 2025 | Keveyis |
| Tolmar, INC. | $32.52 | 2025 | Jatenzo |
| Inspire Medical Systems, INC. | $30.18 | 2024 | Inspire |
| Otsuka America Pharmaceutical, INC. | $29.75 | 2025 | Rexulti |
| Corcept Therapeutics | $25.10 | 2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.33 | 2025 | Caplyta |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $21.01 | 2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $20.70 | 2025 | Breztri |
| Merck Sharp & Dohme LLC | $14.68 | 2025 | Capvaxive, Gardasil 9 |
| Antares Pharma, INC. | $13.55 | 2024 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.